• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ampio Pharmaceuticals Inc. (Amendment)

    2/2/23 12:36:29 PM ET
    $AMPE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPE alert in real time by email
    SC 13G/A 1 d628344dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*

     

     

    Ampio Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, $.0001 par value per share

    (Title of Class of Securities)

    03209T109

    (CUSIP Number)

    December 31, 2022**

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1 (c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **

    Date of the most recent required filing.

    The information in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 03209T109  

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Bruce E. Terker (1)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Pennsylvania

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      960,150 (1)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      960,150 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      960,150 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.36%

    12  

      TYPE OF REPORTING PERSON (see instructions)

     

      IN


    CUSIP No. 03209T109  

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Ballyshannon Partners, L.P. (IRS Identification No. 23-2751854) (2)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Pennsylvania

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      454,223 (2)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      454,223 (2)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      454,223 (2)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.01%

    12  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN


    CUSIP No. 03209T109  

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Ballyshannon Family Partnership, L.P. (IRS Identification No. 23-3086095) (3)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Pennsylvania

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      179,378 (3)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      179,378 (3)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      179,378 (3)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      1.19%

    12  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN


    CUSIP No. 03209T109  

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Insignia Partners, L.P. (Identification No. 23-3054280) (4)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Pennsylvania

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      0 (4)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      0 (4)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0 (4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.00%

    12  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN


    CUSIP No. 03209T109  

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Odyssey Capital Group, L.P. (Identification No. 23-2600849) (5)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Pennsylvania

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      326,549 (5)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      326,549 (5)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      326,549 (5)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      2.16%

    12  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN


    CUSIP No. 03209T109

      
    Iten 1(a).    Name of Issuer
       Ampio Pharnaceuticals, Inc.
    Item 1(b).    Address of Issuer’s Principal Executive Offices:
       373 Inverness Parkway, Suite 200
       Englewood, CO 80112
    Item 2(a).    Name of Person Filing:
       Bruce E. Terker (1)*
       Ballyshannon Partners, L.P. (2)
       Ballyshannon Family Partnership, L.P. (3)
       Insignia Partners, L.P. (4)
       Odyssey Capital Group, L.P. (5)
    Item 2(b).    Address of Principal Business Office or, in none, Residence:
       950 West Valley Road, Suite 2900
       Wayne, PA 19087
    Item 2(c).    Citizenship:
       Bruce E. Terker is a US Citizen (1)
       Ballyshannon Partners, L.P. – Pennsylvania USA (2)
       Ballyshannon Family Partnership, L.P. – Pennsylvania USA (3)
       Insignia Partners, L.P. – Pennsylvania, USA (4)
       Odyssey Capital Group, L.P. – Pennsylvania, USA (5)
    Item 2(d).    Title of Class of Securities:
       Common Stock, $.0001 par value per share
    Item 2(e).    CUSIP Number 03209T109

     

    *

    Bruce E. Terker is the Sole Owner of Ballyshannon Partners, Inc., the General Partner of (2) Ballyshannon Partners, L.P., (3) Ballyshannon Family Partnership, L.P., (4) Insignia Partners, L.P. and is the Sole Owner of Odyssey Capital Group, Inc., the General Partner of (5) Odyssey Capital Group, L.P.


    CUSIP No. 03209T109

     

    Item 3.

      

    If this Statement is filed pursuant to 240.13d-1(b) or (c), check whether the person filing is a:

       (a)   ☐    Broker or dealer registered under Section 15 of the Act;
       (b)   ☐    Bank as defined in Section 3(a)(6) of the Act;
       (c)   ☐    Insurance company as defined in Section 3(a)(19) of the Act;
       (d)   ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
       (e)   ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
       (f)   ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
       (g)   ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
       (h)   ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
       (i)   ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
       (j)   ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
       (k)   ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13-d1(b)(1)(ii)(J), please specify the type of institution:

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    * Bruce E. Terker is the beneficial owner of 960,150 shares of common stock.    Bruce E. Terker is the Sole Owner of Ballyshannon Partners, Inc., the General Partner of (2) Ballyshannon Partners, L.P., (3) Ballyshannon Family Partnership, L.P., (4) Insignia Partners, L.P., and is the Sole Owner of Odyssey Capital Group, Inc. the General Partner of (5) Odyssey Capital Group, L.P.

     

    (a)   Amount Beneficially Owned

          (1) 960,150
    (Mr. Terker may be deemed a beneficial owner of the shares held by
    (2) Ballyshannon Partners, L.P., (3) Ballyshannon Family Partnership, L.P.,
    (4) Insignia Partners, L.P. and (5) Odyssey Capital Group, L.P. because
    he is the sole owner of the General Partner of those partnerships.)
         

    (2) 454,223

         

    (3) 179,378

                (4) 0
         

    (5) 326,549

         

     

    (b)   Percent of Class:

        

       (1) 6.36%
         

    (2) 3.01%

         

    (3) 1.19%

         

    (4) 0.00%

         

    (5) 2.16%

         

     

    (c)   Number of shares as to which such person has:

         

    (i) sole power to vote or to direct the vote:

      

       0
         

     

    (ii)  shared power to vote or to direct the vote:

       

       (1) 960.150
         

    (2) 454,223

         

    (3) 179,378

          (4) 0
         

    (5) 326,549

         

     

    (iii)  sole power to dispose or direct the disposition of:

       

       0
         

     

    (iv) shared power to dispose or to direct the disposition of:

      

       (1) 960,150
         

    (2) 454,223

         

    (3) 179,378

          (4) 0
         

    (5) 326,549

         

     


    CUSIP No. 03209T109

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    N/A

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    N/A

    Item 8. Identification and Classification of Members of the Group.

    N/A

    Item 9. Notice of Dissolution of Group.

    N/A

    Item 10. Certification.

    N/A


    CUSIP No. 03209T109

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:    February 2, 2023   /s/ Bruce E. Terker
      Bruce E. Terker
      Ballyshannon Partners, L.P.
      By: Ballyshannon Partners, Inc., its General Partner
      By:   /s/ Bruce E. Terker
      Name:   Bruce E. Terker
      Title:   President of the General Partner
     

    Ballyshannon Family Partnership, L.P.

      By: Ballyshannon Partners, Inc., its General Partner
      By:   /s/ Bruce E. Terker
      Name:   Bruce E. Terker
      Title:   President of the General Partner
     

    Insignia Partners, L.P.

      By: Ballyshannon Partners, Inc., its General Partner
      By:   /s/ Bruce E. Terker
      Name:   Bruce E. Terker
      Title:   President of the General Partner
     

    Odyssey Capital Group, L.P.

      By: Odyssey Capital Group, Inc., its General Partner
      By:   /s/ Bruce E. Terker
      Name:   Bruce E. Terker
      Title:   Chairman of the General Partner


    CUSIP No. 03209T109

    AGREEMENT TO JOINTLY FILE SCHEDULE 13G

    AGREEMENT dated as of February 2, 2023 by and among Bruce E. Terker, Ballyshannon Partners, L.P., Ballyshannon Family Partnership, L.P., Insignia Partners, L.P. and Odyssey Capital Group, L.P. (collectively, the “Reporting Persons”).

    WHEREAS, pursuant to paragraph (k) of Rule 13d-1 promulgated under Subsection 12(d)(1) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Reporting Persons hereto have decided to satisfy their filing obligation under the Exchange Act by a single joint filing:

    NOW, THEREFORE, the Reporting Persons hereby agree as follows:

     

    1.

    The Schedule 13G with respect to Ampio Pharmaceuticals, Inc. to which this is attached as Exhibit A, is filed on behalf of each of the Reporting Persons.

     

    2.

    Each Reporting Person is responsible for the completeness and accuracy of the information concerning such Reporting Person contained therein.

    IN WITNESS WHEREOF, the undersigned hereunto set their hands as of the date first above written.

     

    Date:    February 2, 2023   /s/ Bruce E. Terker
      Bruce E. Terker
      Ballyshannon Partners, L.P.
      By: Ballyshannon Partners, Inc., its General Partner
      By:   /s/ Bruce E. Terker
      Name:   Bruce E. Terker
      Title:   President of the General Partner
     

    Ballyshannon Family Partnership, L.P.

      By: Ballyshannon Partners, Inc., its General Partner
      By:   /s/ Bruce E. Terker
      Name:   Bruce E. Terker
      Title:   President of the General Partner
     

    Insignia Partners, L.P.

      By: Ballyshannon Partners, Inc., its General Partner
      By:   /s/ Bruce E. Terker
      Name:   Bruce E. Terker
      Title:   President of the General Partner
     

    Odyssey Capital Group, L.P.

      By: Odyssey Capital Group, Inc., its General Partner
      By:   /s/ Bruce E. Terker
      Name:   Bruce E. Terker
      Title:   Chairman of the General Partner


    EXHIBIT A

    Get the next $AMPE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMPE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMPE
    Financials

    Live finance-specific insights

    See more
    • Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock

      ENGLEWOOD, Colo., May 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 8, 2023. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on June 8, 2023. Shares of Series D Preferred Stock will be uncertificated and represented in book-entry form.

      5/26/23 4:40:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Pharmaceuticals, Inc. to Hold Conference Call

      ENGLEWOOD, Colo., April 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, announced that the Company will be hosting a conference call on April 28, 2022 at 8am EDT regarding the update from the Food and Drug Administration with respect to its AP-013 study.  Conference Call Details Date/Time: April 28, 2022 at 8am EDT Title: Investor Update Call - FDA Response Letter AP-01

      4/27/22 4:45:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Pharmaceuticals, Inc. to Hold Fourth Quarter 2021 Earnings and Business Update Call

      ENGLEWOOD, Colo., March 23, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, announced that the Company will be hosting its fourth quarter earnings and business update call March 29 at 4:30pm EST.  Conference Call Details Date/Time: March 29, 2022, at 4:30 pm EST Conferencing Link: https://event.on24.com/wcc/r/3683372/9CD2C8B658E56541C487F44C34E897BBAccess Code:  66744 Canada dial-in number (Toll Free): 1 833 950 0062 Canad

      3/23/22 8:30:00 AM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Ampio Pharmaceuticals Inc.

      15-12G - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

      4/15/24 4:15:06 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25 filed by Ampio Pharmaceuticals Inc.

      25 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

      4/4/24 1:32:03 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

      3/25/24 5:25:17 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Buchi J Kevin

      4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)

      6/13/23 12:07:57 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Buchi J Kevin

      4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)

      6/9/23 2:26:37 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Martino Michael A

      4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)

      5/26/23 1:30:43 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital resumed coverage on Ampio Pharmaceuticals with a new price target

      Roth Capital resumed coverage of Ampio Pharmaceuticals with a rating of Buy and set a new price target of $4.00

      1/24/21 2:54:22 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation

      ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. Further discussion is included in footnote 2 of the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is

      4/3/24 2:33:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Announces Voluntary Delisting and SEC Deregistration

      ENGLEWOOD, Colo., March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today notified the NYSE American of its intention to voluntarily delist its shares of common stock from the NYSE American. The Company intends to file a Form 25 with

      3/25/24 5:00:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Provides Update on Results from Pre-IND Enabling Studies

      ENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.  Ampio reported that the efficacy results of these studies do not support an Investigational New Drug ("IND") submission which was anticipated in early 2025. Specifically, whereas previous smaller studies had demonstrated that OA-201 showed efficacy versus saline control to reduce p

      2/14/24 5:45:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    Leadership Updates

    Live Leadership Updates

    See more
    • Ampio Expands Board of Directors with Addition of Elizabeth Varki Jobes

      ENGLEWOOD, Colo., Feb. 10, 2022 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointment of Elizabeth Varki Jobes, Esq. to the Company's Board of Directors. The appointment of Ms. Jobes expands the Company's Board of Directors from seven members to eight. "We welcome Elizabeth as an addition to our Board of Directors as we enter into a pivotal period at Ampio," said Mike Martino, Chairman and CEO of Ampio. "Throughout her impress

      2/10/22 9:00:00 AM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ampio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)

      12/7/23 10:20:57 AM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ampio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)

      2/2/23 12:36:29 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ampio Pharmaceuticals Inc.

      SC 13G - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)

      7/8/22 4:57:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care